Article

COA Submits Comments on CMS' Proposed CAR T-Cell Coverage Decision

The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy.

The Community Oncology Alliance (COA) has submitted formal comments to CMS regarding the agency's proposed national coverage determination for chimeric antigen receptor (CAR) T-cell therapy, saying that while they are pleased with the direction of covering the therapy, they have concerns with the language included in the memo.

According to COA, CMS should not limit CAR T-cell coverage to hospitals, with many community oncology practices having the experience and capability to administer the therapy. Read the full comment letter.

Related Videos
Lalan Wilfong, MD
Dr Kimlin Tam Ashing
Mike Fazio, Navista, Cardinal Health
Dr Kimlin Tam Ashing
Andrew Kuykendall, MD, Moffitt Cancer Center
John Michael O'Brien, PharmD, MPH
Frederick L Locke, MD, Moffitt
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Erin Weber, MS
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo